Former bluebird execs hope to fly new startup to ‘cutting edge’ of gene therapy delivery tech
The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. | The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. Now, a new startup founded by two genetic medicine luminaries and run by former executives from bluebird bio is officially emerging from stealth mode to reveal its solutions to the industry.